4//SEC Filing
Aperture Venture Partners IV, L.P. 4
Accession 0000899243-19-013254
CIK 0001563880other
Filed
May 12, 8:00 PM ET
Accepted
May 13, 5:01 PM ET
Size
10.8 KB
Accession
0000899243-19-013254
Insider Transaction Report
Form 4
Aperture Venture Partners IV, L.P.
10% Owner
Transactions
- Conversion
Common Stock
2019-05-09+232,963→ 232,963 total - Conversion
Series C Preferred Stock
2019-05-09−2,054,795→ 0 total→ Common Stock (232,963 underlying) - Purchase
Common Stock
2019-05-09$10.00/sh+112,000$1,120,000→ 344,963 total
Aperture Ventures IV Management, LLC
10% Owner
Transactions
- Conversion
Common Stock
2019-05-09+232,963→ 232,963 total - Purchase
Common Stock
2019-05-09$10.00/sh+112,000$1,120,000→ 344,963 total - Conversion
Series C Preferred Stock
2019-05-09−2,054,795→ 0 total→ Common Stock (232,963 underlying)
Footnotes (2)
- [F1]On May 9, 2019, the Series C Preferred Stock, and the dividends that had accrued thereon to date, converted into Common Stock on a 9.5-for-one basis without payment of further consideration automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
- [F2]Aperture Ventures IV Management, LLC, the general partner of Aperture Venture Partners IV, L.P., has sole voting and investment control with respect to shares of the Issuer's common stock held by Aperture Venture Partners IV, L.P.
Documents
Issuer
Trevi Therapeutics, Inc.
CIK 0001563880
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001659119
Filing Metadata
- Form type
- 4
- Filed
- May 12, 8:00 PM ET
- Accepted
- May 13, 5:01 PM ET
- Size
- 10.8 KB